CANCER CENTER CALGB PARTICIPATION

癌症中心 CALGB 参与

• 批准号: 6376690
• 负责人: HYMAN MUSS
• 金额: $ 14.52万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-20 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6376690
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (adapted from the applicant's abstract): The Vermont Cancer Center (VCC), an NCI designated Comprehensive Cancer Center, joined the CALGB in 1995. In that short time the VCC has made significant headway in becoming a major participant in CALGB activities. Eight VCC members have made major commitments to supporting CALGB efforts. Dr. Hyman Muss continues to be extremely active in CALGB and serves as the Co-Chair of the Working Group for the Elderly and the Vice Chair of the Breast Cancer Committee, in addition to chairing two CALGB protocols (8869 and 9670). Dr. Steven Grunberg, a member of the Clinical Economics Committee, is currently developing a clinical protocol that will compare cost with symptom control for antiemetics. Dr. David Krag is an active member of the Breast Core Committee and is helping CALBG develop a protocol for sentinel node staging for women with early stage breast cancer. Dr. Seth Harlow will assume Dr. Krag's role as member of the Surgery Committee. Dr. Donald Weaver participates extensively in pathology group activities and has a major interest in breast cancer. Drs. Michael Cooper, Barbara Grant, and Richard Branda have major interest in urologic cancer, leukemia and lymphoma, and nutrition and cancer, respectively, and have developed concepts for CALGB clinical investigations. The development of multidisciplinary, disease-site oriented, affinity groups within our Center has established major liaisons between laboratory and clinical scientists. This will strengthen our institutional commitment to the group and allow VCC members to develop innovative companion trials for the CALGB. Recently, Drs. Grant and Branda presented two concepts-one related to assessing the importance of folate status on chemotherapy toxicity in women with early breast cancer, and a second that utilizes a novel reporter gene (hprt) to monitor and possibly define women with early stage breast cancer who might be at high risk for developing secondary acute nonlymphocytic leukemia. Drs. Weaver and other VCC scientists are drafting a concept that will explore the role of erbB-2 associated signaling proteins as mediators of apoptosis for women with early stage breast cancer treated with anthracyclines (CALGB 8541). We anticipate a major increase in accrual in the next year. The Green Mountain Oncology Group (CCOP) selected the VCC as its research base beginning in April, 1997. In one month they have entered 10 patients on CALGB protocols. Two new faculty will join the VCC this summer who have major interests in genetics and high-dose therapy; it is anticipated they will be active in CALGB activities. Also, we are developing a major outreach program and expect to add several affiliates with interest in clinical trials. In addition, we have developed a high-dose chemotherapy autologous stem cell support program and expect to become a CALGB Transplant Center by the start of the next funding period.

描述(摘自申请者的摘要)：佛蒙特州癌症 中心(VCC)，NCI指定的综合癌症中心，加入了 CALGB于1995年成立。在这么短的时间内，VCC在 成为CALGB活动的主要参与者。八个VCC成员拥有 做出了支持CALGB努力的重大承诺。海曼·穆斯博士 继续在CALGB中非常活跃，并担任 老年人工作组和乳腺癌副主席 委员会，除了主持两项CALGB议定书(8869和9670)。Dr。 史蒂文·格伦伯格，临床经济委员会成员，目前 开发一种临床方案，将成本与症状控制进行比较 止吐药。David Krag博士是乳房核心组织的活跃成员 委员会，正在帮助CALBG开发用于前哨节点分期的协议 适用于患有早期乳腺癌的女性。赛斯·哈洛博士将假定哈洛博士。 克莱格作为手术委员会成员的角色。唐纳德·韦弗博士 广泛参与病理小组活动，并有专业的 对乳腺癌的兴趣。迈克尔·库珀博士、芭芭拉·格兰特博士和理查德博士 布兰达对泌尿系癌症、白血病和淋巴瘤非常感兴趣， 营养和癌症，并提出了CALGB的概念 临床调查。多学科、多病位的发展 我们中心内的定向、亲和力团体已经建立了重要的联系 实验室和临床科学家之间的关系。这将加强我们的 对集团的机构承诺，并允许VCC成员发展 CALGB的创新伙伴试验。最近，格兰特博士和布兰达 提出了两个概念--一个与评估叶酸的重要性有关 早期乳腺癌妇女的化疗毒性状况，以及 第二，利用一种新的报告基因(Hprt)来监测并可能 定义患有早期乳腺癌的女性可能是乳腺癌的高危人群 发展为继发性急性非淋巴细胞白血病。韦弗博士和其他人 VCC的科学家正在起草一个概念，将探索erbB-2的作用 相关信号蛋白作为早期糖尿病患者细胞凋亡的介导物 使用蒽环类药物治疗晚期乳腺癌(CALGB 8541)。我们期待着 下一年应计项目的大幅增加。绿山肿瘤学 集团(CCOP)从1997年4月开始选择VCC作为其研究基地。 在一个月内，他们已经按照CALGB方案进入了10名患者。两个新的 教员将于今年夏天加入VCC，他们对遗传学有重大兴趣 和高剂量治疗；预计它们将在CALGB中发挥作用 活动。此外，我们正在制定一项重要的外展计划，预计将 增加几家对临床试验感兴趣的附属公司。此外，我们 已经开发出一种大剂量化疗自体干细胞支持计划 并希望在下一年开始时成为CALGB移植中心 资助期。